EFFECTS OF PEG RHUMGDF ON PLATELET LIFESPAN, PRODUCTION & FUNCTION

PEG RHUMGDF 对血小板寿命和产量的影响

• 批准号: 6565713
• 负责人: LAURENCE A HARKER
• 金额: $ 29.31万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-12-01 至 2002-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6565713
• 关键词: blood volume; bone marrow; cell population study; clinical research; drug administration routes; growth factor receptors; hematopoiesis; human subject; human therapy evaluation; megakaryocytes; platelet derived growth factor; platelets; recombinant proteins; thrombopoietic factor

The objectives of this proposal are evaluate, in normal volunteers, the effects of administering bolus PEG-rHuMGDF (3 ug/kg) subcutaneously on marrow megakaryocytopoiesis, and the viability and function of the resulting platelet product. Two cohorts of volunteers will be studied. Each cohort will receive either PEG-rHuMGDF (3 ug/kg), or placebo in a 3:1 ratio, respectively. On day 8 and day 18, we will measure changes in marrow megakaryocytopoiesis; determine the deterations in platelet number, volume, lifespan, and turnover; evaluate the modulating effects of PEG-rHuMGDF on platelet function; and, evaluate the changes in endogenous thrombopoietin (TPO) and platelet (TPO) receptor numbers.

该提案的目的是在正常志愿者中评估皮下推注 PEG-rHuMGDF (3 ug/kg) 对骨髓巨核细胞生成的影响，以及所得血小板产品的活力和功能。将研究两组志愿者。每个队列将分别接受 3:1 比例的 PEG-rHuMGDF (3 ug/kg) 或安慰剂。第8天和第18天，我们将测量骨髓巨核细胞生成的变化；确定血小板数量、体积、寿命和周转率的变化；评价PEG-rHuMGDF对血小板功能的调节作用；并评估内源性血小板生成素（TPO）和血小板（TPO）受体数量的变化。